Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Al B. Benson III, MD, Panel Chair, has disclosed that he receives grant/research support from Acerta Pharma; Bristol-Myers Squibb Company; Celgene Corporation; Infi nity Pharmaceuticals; MedImmune Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Taiho Parmaceuticals Co., Ltd. He also receives consulting fees/honoraria from and serves as a scientific advisor for AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim GmbH; Boston Biomedical; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; EMO Serono; Exelixis Inc.; Genentech, Inc.; Guidant Corporation; Halozyme, Inc.; Helsinn Therapeutics; ImmunoGen, Inc.; Lexicon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Opsona Therapeutics; Pfizer Inc.; Purdue Pharma LP; and Taiho Parmaceuticals Co., Ltd.
Alan P. Venook, MD, Panel Vice Chair, has disclosed that he serves as a scientifi c advisor for Bayer HealthCare; Bristol-Myers Squibb Company; Genentech, Inc.; Merck & Co., Inc.; and Taiho Pharmaceuticals Co., Ltd. He also receives grant/research support from Genentech, Inc., and Merck & Co., Inc.
Stacey Cohen, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.